Epclusa User Guide
Epclusa is a compound formulation composed of Sofosbuvir and Velpatasvir. It is the world's first oral antiviral drug for the full genotype hepatitis C virus (HCV), with a cure rate of over 95%. This drug inhibits virus replication through a dual mechanism, is suitable for all HCV genotype infections, and has significant therapeutic effects on patients with cirrhosis.
1. Basic information of the drug
Jisanda was approved for market by the FDA in 2016. Each tablet contains 400mg of sofosbuvir and 100mg of velpatasvir. As a pan genotypic DAA drug, its breakthrough lies in the fact that it can be used without the need for genotyping testing.
2. Mechanism of action
(1) Sofosbuvir: As an NS5B polymerase inhibitor, it terminates replication by incorporating viral RNA strands; (2) Vepatasvir: targets the NS5A protein and disrupts the assembly of viral replication complexes. The synergistic effect of the two covers all six genotypes of HCV.
3 Indications Scope
Suitable for adult patients with chronic hepatitis C of all genotypes (1-6), including those without cirrhosis or compensated cirrhosis (Child Pugh A grade). Especially advantageous for patients with previous treatment failures, HIV co infection, and liver transplantation.
4 Medication plan
The standard course of treatment is one tablet per day (on an empty stomach or after meals) for 12 weeks. Decompensated cirrhosis (Child Pugh B/C grade) requires the use of ribavirin in combination. Patients with renal insufficiency do not need to adjust the dosage, and severe liver function damage needs to be evaluated before use.
5 Drug Interactions
Combined use with potent CYP3A4 inducers (such as rifampicin) can reduce efficacy; Combined use with amiodarone may cause severe bradycardia. Special attention should be paid to taking proton pump inhibitors at an interval of 4 hours.
6 Adverse Reaction Monitoring
Mild reactions such as common headaches (22%) and fatigue (15%). Be alert to rare but severe symptomatic bradycardia, and patients using cardiac monitoring devices should closely monitor changes in their electrocardiogram.
Disclaimer：《Epclusa User Guide》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！